Medipharm Labs Corp
TSX:LABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medipharm Labs Corp
Cash Equivalents
Medipharm Labs Corp
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medipharm Labs Corp
TSX:LABS
|
Cash Equivalents
CA$10.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash Equivalents
$1.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
17%
|
CAGR 10-Years
8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash Equivalents
CA$169m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
24%
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash Equivalents
$791.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
99%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash Equivalents
CA$5.4m
|
CAGR 3-Years
161%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-32%
|
|
Medipharm Labs Corp
Glance View
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.
See Also
What is Medipharm Labs Corp's Cash Equivalents?
Cash Equivalents
10.8m
CAD
Based on the financial report for Dec 31, 2025, Medipharm Labs Corp's Cash Equivalents amounts to 10.8m CAD.
What is Medipharm Labs Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash Equivalents growth was -8%. The average annual Cash Equivalents growth rates for Medipharm Labs Corp have been -23% over the past three years , -11% over the past five years .
